Stoke Therapeutics, a preclinical biotech developing RNA-targeted therapies for rare genetic diseases, raised $142 million by offering 7.9 million shares at $18, above the range of $14 to $16. The company had previously filed to offer 6.7 million shares.
Stoke Therapeutics plans to list on the Nasdaq under the symbol STOK. J.P. Morgan, Cowen and Credit Suisse acted as joint book-running managers on the deal.
